Predictors of fibrosis, clinical events, and mortality in MASLD: Data from the Global-MASLD study.

Λεπτομέρειες βιβλιογραφικής εγγραφής
Τίτλος:	Predictors of fibrosis, clinical events, and mortality in MASLD: Data from the Global-MASLD study.
Συγγραφείς:	Younossi ZM; The Global NASH Council (GNC), Washington, District of Columbia, USA.; The Global Center for Liver Outcomes and Policy Research, Georgetown University School of Medicine, Washington, District of Columbia, USA., de Avila L; The Global NASH Council (GNC), Washington, District of Columbia, USA., Petta S; The Global NASH Council (GNC), Washington, District of Columbia, USA.; Section of Gastroenterology, PROMISE Department, University of Palermo, Palermo, Italy., Hagström H; The Global NASH Council (GNC), Washington, District of Columbia, USA.; Department of Upper GI Diseases, Division of Hepatology, Karolinska University Hospital, Stockholm, Sweden., Kim SU; The Global NASH Council (GNC), Washington, District of Columbia, USA.; Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea, Republic of South., Nakajima A; The Global NASH Council (GNC), Washington, District of Columbia, USA.; Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan., Crespo J; The Global NASH Council (GNC), Washington, District of Columbia, USA.; Gastroenterology and Hepatology Department, Clinical and Translational Research in Digestive Diseases, Valdecilla Research Institute (IDIVAL), Marques de Valdecilla University Hospital, Santander, Spain., Castera L; The Global NASH Council (GNC), Washington, District of Columbia, USA.; Department of Hepatology, Hospital Beaujon, Assistance Publique-Hôpitaux de Paris, Université Paris-Cité, Paris, France., Alkhouri N; The Global NASH Council (GNC), Washington, District of Columbia, USA.; Summit Clinical Research, San Antonio, Texas, USA., Zheng MH; The Global NASH Council (GNC), Washington, District of Columbia, USA.; Department of Hepatology, MAFLD Research Center, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China., Treeprasertsuk S; The Global NASH Council (GNC), Washington, District of Columbia, USA.; Department of Internal Medicine, Division of Gastroenterology, Chulalongkorn University, Bangkok, Thailand., Ananchuensook P; The Global NASH Council (GNC), Washington, District of Columbia, USA.; Department of Internal Medicine, Division of Gastroenterology, Chulalongkorn University, Bangkok, Thailand., Shalimar; The Global NASH Council (GNC), Washington, District of Columbia, USA.; Department of Gastroenterology and Human Nutrition Unit, All India Institute of Medical Sciences, New Delhi, India., Tsochatzis E; The Global NASH Council (GNC), Washington, District of Columbia, USA.; University College London Institute for Liver and Digestive Health, Royal Free Hospital, London, UK., Trivikrama SK; The Global NASH Council (GNC), Washington, District of Columbia, USA.; Department of Gastroenterology, Sree Gokulam Medical College and Research Foundation, Trivandrum, Kerala, India., Balakumaran LK; The Global NASH Council (GNC), Washington, District of Columbia, USA.; Population Health and Research Institute, Medical College P O, Trivandrum, Kerala, India., Fan JG; The Global NASH Council (GNC), Washington, District of Columbia, USA.; Department of Gastroenterology, Xinhua Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China., Roberts SK; The Global NASH Council (GNC), Washington, District of Columbia, USA.; Alfred Hospital Gastroenterology Department, Monash University, Melbourne, Australia., Alswat K; The Global NASH Council (GNC), Washington, District of Columbia, USA.; Department of Medicine, College of Medicine, Liver Disease Research Center, King Saud University, Riyadh, Saudi Arabia., Wong VW; The Global NASH Council (GNC), Washington, District of Columbia, USA.; Department of Medicine and Therapeutics, Medical Data Analytics Center, The Chinese University of Hong Kong, Hong Kong, China., Yilmaz Y; The Global NASH Council (GNC), Washington, District of Columbia, USA.; Department of Gastroenterology, School of Medicine, Recep Tayyip Erdogan University, Rize, Türkiye., Dunn W; Internal Medicine, Kansas University Medical Center, Kansas City, Kansas, USA., Francque S; The Global NASH Council (GNC), Washington, District of Columbia, USA.; Department of Gastroenterology and Hepatology, Antwerp University Hospital, Edegem, Belgium., Cordie A; The Global NASH Council (GNC), Washington, District of Columbia, USA.; Endemic Medicine Department, Cairo University Hospitals HIV Clinic, Cairo University Hospitals, Cairo, Egypt., Yu ML; The Global NASH Council (GNC), Washington, District of Columbia, USA.; Department of Internal Medicine, Hepatobiliary Division, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan., Ekstedt M; Department of Gastroenterology and Hepatology, Department of Health, Medicine, and Caring Sciences, Linköping University, Linköping, Sweden., Goh GB; The Global NASH Council (GNC), Washington, District of Columbia, USA.; Department of Gastroenterology & Hepatology, Singapore General Hospital, Singapore, Singapore., Oliveira CP; The Global NASH Council (GNC), Washington, District of Columbia, USA.; Department of Gastroenterology, Faculdade Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil., Pessoa MG; The Global NASH Council (GNC), Washington, District of Columbia, USA.; Department of Gastroenterology, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo - HCFMUSP, São Paulo, Brazil., Chan WK; The Global NASH Council (GNC), Washington, District of Columbia, USA.; Gastroenterology and Hepatology Unit, Department of Medicine, University of Malaya, Kuala Lumpur, Malaysia., Fernandez MIC; The Global NASH Council (GNC), Washington, District of Columbia, USA.; Department of Research and Teaching, Institute of Gastroenterology, University of Medical Sciences of Havana, Havana, Cuba., Duseja A; The Global NASH Council (GNC), Washington, District of Columbia, USA.; Department of Hepatology, Postgraduate Institute of Medical Education and Research, Chandigarh, India., Arab JP; The Global NASH Council (GNC), Washington, District of Columbia, USA.; Department of Internal Medicine, Division of Gastroenterology, Hepatology, and Nutrition, Stravitz-Sanyal Institute for Liver Disease and Metabolic Health, Virginia Commonwealth University School of Medicine, Richmond, United States., Papatheodoridis G; The Global NASH Council (GNC), Washington, District of Columbia, USA.; 1st Academic Department of Gastroenterology, Medical School of National and Kapodistrian University of Athens, General Hospital of Athens 'Laiko', Athens, Greece., Sebastiani G; The Global NASH Council (GNC), Washington, District of Columbia, USA.; Department of Medicine, Division of Gastroenterology and Hepatology, McGill University Health Centre, Montreal, Canada., Villela-Nogueira C; The Global NASH Council (GNC), Washington, District of Columbia, USA.; Internal Medicine Department, Hepatology Division, School of Medicine, Clementino Fraga Filho University Hospital, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil., D'Ambrosio R; Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy., Lampertico P; The Global NASH Council (GNC), Washington, District of Columbia, USA.; Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy., AlNaamani KM; The Global NASH Council (GNC), Washington, District of Columbia, USA.; Department of Medicine, Division of Gastroenterology and Hepatology, The Medical City for Military and Security Services, Muscat, Oman., Holleboom AG; The Global NASH Council (GNC), Washington, District of Columbia, USA.; Department of Vascular Medicine, Amsterdam University Medical Center, Amsterdam, Netherlands., Valsan A; The Global NASH Council (GNC), Washington, District of Columbia, USA.; Centre for Metabolic Liver Disease and Integrated Liver Care Unit, Amrita Institute of Medical Sciences, Kochi, Kerala, India., Venu A; Centre for Metabolic Liver Disease and Integrated Liver Care Unit, Amrita Institute of Medical Sciences, Kochi, Kerala, India., El-Kassas M; The Global NASH Council (GNC), Washington, District of Columbia, USA.; Endemic Medicine Department, Faculty of Medicine, Helwan University, Cairo, Egypt., Pennisi G; Section of Gastroenterology, PROMISE Department, University of Palermo, Palermo, Italy., Shang Y; Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden., Liu WY; Department of Endocrinology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China., Lee HW; Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea, Republic of South., Kobayashi T; Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan., Kakizaki S; The Global NASH Council (GNC), Washington, District of Columbia, USA.; Department of Clinical Research, NHO Takasaki General Medical Center, Takasaki, Japan., Caussy C; The Global NASH Council (GNC), Washington, District of Columbia, USA.; Département Endocrinologie, Diabète et Nutrition, Hôpital Lyon Sud, Hospices Civils de Lyon, Pierre-Bénite, Lyon, France., Pearlman B; The Global NASH Council (GNC), Washington, District of Columbia, USA.; Department of Graduate Medical Education, Hamilton Medical Center, Medical College of Georgia, Dalton, USA., Iruzubieta P; Gastroenterology and Hepatology Department, Clinical and Translational Research in Digestive Diseases, Valdecilla Research Institute (IDIVAL), Marques de Valdecilla University Hospital, Santander, Spain., Nadeem R; Arizona Liver Health, Chandler, Arizona, USA., Cinque F; Department of Medicine, Division of Gastroenterology and Hepatology, McGill University Health Centre, Montreal, Canada., Neonaki A; 1st Academic Department of Gastroenterology, Medical School of National and Kapodistrian University of Athens, General Hospital of Athens 'Laiko', Athens, Greece., Zoncapé M; Liver Unit, Department of Internal Medicine, University and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, Italy., Yang RX; Department of Gastroenterology, Xinhua Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China., Song SJ; Department of Medicine and Therapeutics, Medical Data Analytics Center, The Chinese University of Hong Kong, Hong Kong, China., Dunn N; Internal Medicine, Kansas University Medical Center, Kansas City, Kansas, USA., Gadi Z; Department of Gastroenterology and Hepatology, Antwerp University Hospital, Edegem, Belgium., Yeh ML; Center of Excellence for Metabolic Associated Fatty Liver Disease, National Sun Yat-sen University, Kaohsiung, Taiwan., Teh KK; Department of Gastroenterology & Hepatology, Singapore General Hospital, Singapore, Singapore., Mahadeva S; Gastroenterology and Hepatology Unit, Department of Medicine, University of Malaya, Kuala Lumpur, Malaysia., Fabian LG; Department of Pathological Anatomy, Institute of Gastroenterology, University of Medical Sciences of Havana, Havana, Cuba., Almohsen A; Department of Medicine, Schulich School of Medicine, Western University & London Health Sciences Centre, London, Ontario, Canada., Leite N; Internal Medicine Department, Hepatology Division, School of Medicine, Clementino Fraga Filho University Hospital, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil., Pugliese N; The Global NASH Council (GNC), Washington, District of Columbia, USA.; Department of Gastroenterology, Division of Internal Medicine and Hepatology, IRCCS Humanitas Research Hospital, Rozzano, Italy., Vessby J; Department of Medical Sciences, Gastroenterology Research Group, Uppsala University, Uppsala, Sweden., Xie C; Division of Hepatology, Avera McKennan Hospital, University Health Center, Sioux Falls, USA., Choudhary NS; Hepatology, and Institute of Liver Transplantation and Regenerative Medicine, Medanta The Medicity, Gurugram, Haryana, India., Friend E; Velocity Clinical Research, Waco, Texas, USA., Poca M; Department of Gastroenterology, CIBEREHD, IR Sant Pau, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain., Kawaguchi T; The Global NASH Council (GNC), Washington, District of Columbia, USA.; Department of Medicine, Division of Gastroenterology, Kurume University School of Medicine, Kurume, Japan., Russo FP; Department of Surgery, Oncology and Gastroenterology, University of Padova Gastroenterology Unit, Azienda Ospedaliera - Universita Padova, Padova, Italy., Gadano A; The Global NASH Council (GNC), Washington, District of Columbia, USA.; Liver Unit, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina., Diaz LA; The Global NASH Council (GNC), Washington, District of Columbia, USA.; Division of Gastroenterology and Hepatology, MASLD Research Center, University of California San Diego, San Diego, California, USA., Singal AK; The Global NASH Council (GNC), Washington, District of Columbia, USA.; Department of Medicine, Division of Gastroenterology, Hepatology, and Nutrition, University of Louisville, Louisville, Kentucky, USA., Segrestin B; The Global NASH Council (GNC), Washington, District of Columbia, USA.; Département Endocrinologie, Diabète et Nutrition, Hôpital Lyon Sud, Hospices Civils de Lyon, Pierre-Bénite, Lyon, France., Gunn N; The Global NASH Council (GNC), Washington, District of Columbia, USA.; Velocity Clinical Research, Waco, Texas, USA., Mauricio D; The Global NASH Council (GNC), Washington, District of Columbia, USA.; Department of Endocrinology & Nutrition, CIBERDEM, IR Sant Pau, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain., Arrese M; The Global NASH Council (GNC), Washington, District of Columbia, USA.; Departamento de Gastroenterología, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile., Fracanzani A; Unit of Metabolic Disease, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy., Lombardi R; Unit of Metabolic Disease, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy., Lam B; The Global NASH Council (GNC), Washington, District of Columbia, USA., Racila A; The Global NASH Council (GNC), Washington, District of Columbia, USA., Alqahtani SA; The Global NASH Council (GNC), Washington, District of Columbia, USA.; Liver, Digestive, and Lifestyle Health Research Section, and Organ Transplant Center of Excellence, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia., Stepanova M; The Global NASH Council (GNC), Washington, District of Columbia, USA.; Beatty Liver and Obesity Research Program, Inova Health System, Falls Church, Virginia, USA.; Center for Outcomes Research in Liver Disease, Washington District of Columbia, USA.
Συλλογικό Έργο:	Global NASH/MASH Council (GNC)
Πηγή:	Hepatology (Baltimore, Md.) [Hepatology] 2026 Jul 01; Vol. 84 (1), pp. 204-215. Date of Electronic Publication: 2025 Nov 13.
Τύπος έκδοσης:	Journal Article
Γλώσσα:	English
Στοιχεία περιοδικού:	Publisher: Wolters Kluwer Health, Inc Country of Publication: United States NLM ID: 8302946 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-3350 (Electronic) Linking ISSN: 02709139 NLM ISO Abbreviation: Hepatology Subsets: MEDLINE
Imprint Name(s):	Publication: 2023- : [Philadelphia] : Wolters Kluwer Health, Inc. Original Publication: Baltimore, MD : Williams & Wilkins, [c1981]-
Ιατρικοί όροι (MeSH):	Liver Cirrhosis/pathology , Liver Cirrhosis/mortality , Liver Cirrhosis/etiology , Liver Cirrhosis/epidemiology , Liver Cirrhosis/diagnosis , Diabetes Mellitus, Type 2/epidemiology , Liver/pathology , Non-alcoholic Fatty Liver Disease/mortality , Non-alcoholic Fatty Liver Disease/pathology , Non-alcoholic Fatty Liver Disease/complications, Obesity/epidemiology ; Humans ; Male ; Female ; Prognosis ; Middle Aged ; Biopsy ; Aged ; Risk Factors ; Adult
Περίληψη:	Background and Aims: Advanced histologic fibrosis is a major predictor of mortality in metabolic dysfunction-associated steatotic liver disease (MASLD). We aimed to identify advanced fibrosis clinical determinants across diverse MASLD populations and to assess the prognostic value of noninvasive markers (NITs) of fibrosis for adverse outcomes. Approach and Results: The Global MASLD (G-MASLD) enrolled biopsy-confirmed MASLD patients with clinical, histologic, and noninvasive test (NIT) data. Factors associated with the presence of advanced histologic fibrosis (F3-F4) in MASLD and clinical outcomes were assessed. There were 17,792 patients with MASLD. Advanced fibrosis (≥F3) was present in 35%. The prevalence of type 2 diabetes (T2D) increased stepwise with fibrosis stage, from 28% in F0 to 70% in F4 (trend p <0.0001). Independent predictors of advanced fibrosis included older age, T2D, and obesity, although the association with obesity varied by region. Among patients with follow-up (mean 6.6 y), 6.5% died and 10.1% experienced a clinical event. Older age, male sex, T2D, and obesity were independent predictors of both mortality and clinical events ( p <0.05). Fibrosis severity, whether defined histologically or by NITs, was strongly associated with higher risks of death and liver-related outcomes (all adjusted HR>1.0, p <0.001). Five-year mortality was 2.1% overall, rising to 8.3% in patients with cirrhosis, and exceeded 10% among those with high-risk NIT score values. Conclusions: In this large global biopsy-based MASLD cohort, advanced fibrosis was highly prevalent and strongly linked to T2D. Both histologic fibrosis and NITs were independent predictors of mortality and clinical outcomes, underscoring the prognostic value of fibrosis assessment with NITs. (Copyright © 2025 American Association for the Study of Liver Diseases.)
References:	Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): A systematic review. Hepatology. 2023;77:1335–1347. Le MH, Le DM, Baez TC, Wu Y, Ito T, Lee EY, et al. Global incidence of non-alcoholic fatty liver disease: A systematic review and meta-analysis of 63 studies and 1,201,807 persons. J Hepatol. 2023;79:287–295. Paik JM, Henry L, Younossi Y, Ong J, Alqahtani S, Younossi ZM. The burden of nonalcoholic fatty liver disease (NAFLD) is rapidly growing in every region of the world from 1990 to 2019. Hepatol Commun. 2023;7:e0251. Younossi ZM, Stepanova M, Rafiq N, Makhlouf H, Younoszai Z, Agrawal R, et al. Pathologic criteria for nonalcoholic steatohepatitis: Interprotocol agreement and ability to predict liver-related mortality. Hepatology. 2011;53:1874–1882. Dulai PS, Singh S, Patel J, Soni M, Prokop LJ, Younossi Z, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. Hepatology. 2017;65:1557–1565. Ekstedt M, Hagström H, Nasr P, Fredrikson M, Stål P, Kechagias S, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015;61:1547–1554. Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149:389–97.e10. Hossain N, Afendy A, Stepanova M, Nader F, Srishord M, Rafiq N, et al. Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009;7:1224–1229; 1229.e1-2. Owrangi S, Paik JM, Golabi P, de Avila L, Hashida R, Nader A, et al. Meta-analysis: Global prevalence and mortality of cirrhosis in metabolic dysfunction-associated steatotic liver disease. Aliment Pharmacol Ther. 2025;61:433–443. Younossi ZM, Yilmaz Y, Yu ML, Wai-Sun Wong V, Fernandez MC, Isakov VA, et al; Global NASH Council. Clinical and patient-reported outcomes from patients with nonalcoholic fatty liver disease across the world: Data from the global nonalcoholic steatohepatitis (NASH)/ non-alcoholic fatty liver disease (NAFLD) Registry. Clin Gastroenterol Hepatol. 2022;20:2296–2306.e6. Younossi ZM, Paik JM, Henry L, Yang J, Fernandes G, Stepanova M, et al. The growing economic and clinical burden of nonalcoholic steatohepatitis (NASH) in the United States. J Clin Exp Hepatol. 2023;13:454–467. Younossi ZM, Tampi R, Priyadarshini M, Nader F, Younossi IM, Racila A. Burden of illness and economic model for patients with nonalcoholic steatohepatitis in the United States. Hepatology. 2019;69:564–572. Macedo Silva V, Freitas M, Xavier S, Boal Carvalho P, Magalhães J, Marinho C, et al. The New FibroScan-AST (FAST) Score: Enhancing diabetes mellitus impact on metabolic-associated fatty liver disease. GE Port J Gastroenterol. 2022;30:422–429. Sanyal AJ, Foucquier J, Younossi ZM, Harrison SA, Newsome PN, Chan WK, et al. Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores. J Hepatol. 2023;78:247–259. Taru MG, Tefas C, Neamti L, Minciuna I, Taru V, Maniu A, et al. FAST and Agile-the MASLD drift: Validation of Agile 3+, Agile 4 and FAST scores in 246 biopsy-proven NAFLD patients meeting MASLD criteria of prevalent caucasian origin. PLoS ONE. 2024;19:e0303971. Golabi P, Otgonsuren M, de Avila L, Sayiner M, Rafiq N, Younossi ZM. Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD). Medicine (Baltimore). 2018;97:e0214. Younossi ZM, Golabi P, Price JK, Owrangi S, Gundu-Rao N, Satchi R, et al. The global epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among patients with type 2 diabetes. Clin Gastroenterol Hepatol. 2024;22:1999–2010.e8. Yeo YH, Zhu Y, Gao J, Liu S, Ni W, Rui F, et al. Anthropometric Measures and mortality risk in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD): A population-based cohort study. Aliment Pharmacol Ther. 2025;62:168–179. Younossi ZM, Zelber-Sagi S, Lazarus JV, Wong VW, Yilmaz Y, Duseja A, et al. Global consensus recommendations for metabolic dysfunction-associated steatotic liver disease and steatohepatitis. Gastroenterology. 2025;169:1017–1032.e2. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81:492–542. Younossi ZM, Wong VW, Tsochatzis EA, Castera L, Betel M, Henry L, et al. Managing MASLD through preventive hepatology: Integrating policy reform, public health, and personalized care. Liver International. 2025;45:e70311.
Contributed Indexing:	Keywords: biomarkers; chronic liver disease; diagnostic thresholds; metabolic syndrome; noncommunicable diseases; outcomes; steatohepatitis; steatotic liver disease
Entry Date(s):	Date Created: 20251113 Date Completed: 20260616 Latest Revision: 20260616
Update Code:	20260616
DOI:	10.1097/HEP.0000000000001617
PMID:	41231627
Βάση Δεδομένων:	MEDLINE

View record from ScienceDirect

Περιγραφή
ISSN:	1527-3350
DOI:	10.1097/HEP.0000000000001617